Literature DB >> 3464201

A blind prometaphase study of Prader-Willi syndrome: frequency and consistency in interpretation of del 15q.

F Labidi, S B Cassidy.   

Abstract

Controversy continues to exist concerning the proportion of individuals with Prader-Willi syndrome who have a chromosome 15 deletion and concerning the reliability with which a cytogenetic service laboratory can accurately perform the appropriate analysis. Blind prometaphase cytogenetic study of 13 individuals from a Prader-Willi syndrome clinic and seven controls has revealed that approximately 70% of accurately diagnosed clinically typical patients with this disorder have an evident deletion of at least 15q12. Blind analysis of panels of chromosome 15 pairs from all cases in this study by the directors of four independent cytogenetic service laboratories demonstrated substantial interobserver consistency in interpretation of results. The possibility of euploid mosaicism for del 15q was investigated, but remains unresolved.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3464201      PMCID: PMC1683985     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  9 in total

1.  Mid-prophase human chromosomes. The attainment of 2000 bands.

Authors:  J J Yunis
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

2.  Deletions of chromosome 15 as a cause of the Prader-Willi syndrome.

Authors:  D H Ledbetter; V M Riccardi; S D Airhart; R J Strobel; B S Keenan; J D Crawford
Journal:  N Engl J Med       Date:  1981-02-05       Impact factor: 91.245

Review 3.  Chromosome 15 anomalies and the Prader-Willi syndrome: cytogenetic analysis.

Authors:  M G Mattei; N Souiah; J F Mattei
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

4.  Prader-Willi syndrome and chromosome 15. A clinical discussion of 20 cases.

Authors:  J F Mattei; M G Mattei; F Giraud
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

5.  The cytogenetic controversy in the Prader-Labhart-Willi syndrome.

Authors:  B G Kousseff
Journal:  Am J Med Genet       Date:  1982-12

6.  Clinical and cytogenetic studies of the Prader-Willi syndrome: evidence of phenotype-karyotype correlation.

Authors:  N Niikawa; S Ishikiriyama
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

7.  Deletion of chromosome 15 (q11-13) in a Prader-Labhart-Willi syndrome clinic population.

Authors:  S B Cassidy; H C Thuline; V A Holm
Journal:  Am J Med Genet       Date:  1984-02

8.  Chromosome 15 abnormalities and the Prader-Willi syndrome: a follow-up report of 40 cases.

Authors:  D H Ledbetter; J T Mascarello; V M Riccardi; V D Harper; S D Airhart; R J Strobel
Journal:  Am J Hum Genet       Date:  1982-03       Impact factor: 11.025

9.  Chromosome 15 in Prader-Willi syndrome.

Authors:  C N Fear; D E Mutton; A C Berry; J Z Heckmatt; V Dubowitz
Journal:  Dev Med Child Neurol       Date:  1985-06       Impact factor: 5.449

  9 in total
  5 in total

1.  The association of Angelman's syndrome with deletions within 15q11-13.

Authors:  M Pembrey; S J Fennell; J van den Berghe; M Fitchett; D Summers; L Butler; C Clarke; M Griffiths; E Thompson; M Super
Journal:  J Med Genet       Date:  1989-02       Impact factor: 6.318

2.  Occupational hydrocarbon exposure among fathers of Prader-Willi syndrome patients with and without deletions of 15q.

Authors:  S B Cassidy; A J Gainey; M G Butler
Journal:  Am J Hum Genet       Date:  1989-06       Impact factor: 11.025

3.  Adults with Prader-Willi syndrome: abnormalities of sleep and behaviour.

Authors:  D J Clarke; J Waters; J A CORBETT
Journal:  J R Soc Med       Date:  1989-01       Impact factor: 5.344

4.  Prader-Willi syndrome: current understanding of cause and diagnosis.

Authors:  M G Butler
Journal:  Am J Med Genet       Date:  1990-03

5.  Visual evoked potentials in Prader-Willi syndrome.

Authors:  P Apkarian; H Spekreijse; E van Swaay; M van Schooneveld
Journal:  Doc Ophthalmol       Date:  1989-04       Impact factor: 2.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.